Hub : Traits :

Relative age voice broke

403 significantly associated models · 34 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	199754486	200391561	1	1	3.7e-08	6.9e-10	1.7e-05	51	NR5A2
2	4	94527983	95955095	1	1	2.0e-08	4.1e-08	1.0e+00	100	HPGDS
3	6	99324687	100719911	1	1	3.5e-08	1.6e-08	5.6e-04	63	RP1-199J3.5
4	6	104478130	106230491	2	1	1.6e-21	1.7e-32	7.2e-13	64	LIN28B
5	10	4716018	5229091	1	1	2.6e-07	1.8e-06	4.6e-01	98	AKR1C2
6	10	116155718	118404700	1	1	1.1e-07	2.6e-04	3.5e-01	94	ATRNL1
7	11	122058476	123525464	1	2	2.7e-10	1.2e-10	1.0e+00	100	C11orf63
8	15	60397836	60938816	1	1	8.9e-08	1.2e-08	6.5e-03	77	ANXA2
9	15	88358250	89773505	1	1	9.0e-08	7.1e-08	6.1e-02	88	DET1
10	16	13697975	14759768	1	1	5.4e-08	8.8e-18	1.9e-11	39	RP11-65J21.3
11	16	89189472	90172696	2	2	4.6e-08	1.9e-06	2.7e-01	95	DPEP1 SPIRE2
12	17	42607368	45796313	20	1	3.3e-15	1.1e-13	1.1e-01	95	LRRC37A
13	20	33197489	34697305	1	1	2.2e-07	1.6e-06	8.2e-01	100	UQCC1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hair Pigment	131.93	4	4	8.9	0.80	2.0e-01	DPEP1 LRRC37A SPIRE2 UQCC1
Tanning	86.00	3	3	6.7	0.00	1.0e+00	DPEP1 SPIRE2 UQCC1
Age when periods started (menarche)	21.74	7	6	13.3	0.97	7.6e-05	ANXA2 ATRNL1 C11orf63 DET1 HPGDS LIN28B RP11-65J21.3
Relative age of first facial hair	21.30	11	10	22.2	0.99	2.1e-09	ANXA2 C11orf63 DET1 DPEP1 HPGDS LIN28B LRRC37A RP11-65J21.3 RP1-199J3.5 SPIRE2 UQCC1
Sitting height	9.37	4	3	6.7	-0.47	5.3e-01	AKR1C2 LRRC37A RP11-65J21.3 UQCC1
Height	9.22	9	9	20.0	0.26	4.7e-01	AKR1C2 ANXA2 C11orf63 DET1 DPEP1 LIN28B LRRC37A RP11-65J21.3 UQCC1
Standing height	8.84	8	7	15.6	0.28	4.6e-01	AKR1C2 C11orf63 DET1 DPEP1 LIN28B LRRC37A RP11-65J21.3 UQCC1
Hair/balding pattern: Pattern 4	8.47	1	1	2.2	0.00	1.0e+00	LRRC37A
Forced expiratory volume in 1-second (FEV1), predicted	6.69	4	3	6.7	0.83	1.7e-01	AKR1C2 C11orf63 LIN28B UQCC1
Trunk predicted mass	6.38	4	3	6.7	0.21	7.9e-01	AKR1C2 LIN28B RP11-65J21.3 UQCC1
Trunk fat-free mass	6.32	4	3	6.7	0.20	8.0e-01	AKR1C2 LIN28B RP11-65J21.3 UQCC1
Hair/balding pattern: Pattern 3	6.21	2	1	2.2	0.00	1.0e+00	LRRC37A NR5A2
Whole body fat-free mass	6.05	4	3	6.7	0.17	8.3e-01	AKR1C2 LIN28B RP11-65J21.3 UQCC1
Whole body water mass	5.89	4	3	6.7	0.16	8.4e-01	AKR1C2 LIN28B RP11-65J21.3 UQCC1
Comparative height size at age 10	5.88	3	1	2.2	0.00	1.0e+00	LRRC37A RP1-199J3.5 UQCC1
Hand grip strength (right)	5.58	3	2	4.4	0.00	1.0e+00	LIN28B LRRC37A UQCC1
Leg fat-free mass (right)	5.53	3	2	4.4	0.00	1.0e+00	AKR1C2 LIN28B UQCC1
Leg predicted mass (right)	5.52	3	2	4.4	0.00	1.0e+00	AKR1C2 LIN28B UQCC1
Lung FVC	5.45	3	3	6.7	0.00	1.0e+00	LIN28B LRRC37A UQCC1
Basal metabolic rate	5.45	4	2	4.4	0.15	8.5e-01	AKR1C2 LIN28B RP11-65J21.3 UQCC1
Leg fat-free mass (left)	5.38	3	2	4.4	0.00	1.0e+00	AKR1C2 LIN28B UQCC1
Leg predicted mass (left)	5.37	3	2	4.4	0.00	1.0e+00	AKR1C2 LIN28B UQCC1
Peak expiratory flow (PEF)	5.29	3	3	6.7	0.00	1.0e+00	LRRC37A RP11-65J21.3 UQCC1
Hand grip strength (left)	5.23	3	2	4.4	0.00	1.0e+00	LIN28B LRRC37A UQCC1
Arm predicted mass (right)	5.16	3	3	6.7	0.00	1.0e+00	AKR1C2 RP11-65J21.3 UQCC1
Arm predicted mass (left)	5.16	3	3	6.7	0.00	1.0e+00	AKR1C2 RP11-65J21.3 UQCC1
Arm fat-free mass (right)	5.14	3	3	6.7	0.00	1.0e+00	AKR1C2 RP11-65J21.3 UQCC1
Arm fat-free mass (left)	5.10	3	2	4.4	0.00	1.0e+00	AKR1C2 RP11-65J21.3 UQCC1
Neuroticism	4.29	3	1	2.2	0.00	1.0e+00	LIN28B LRRC37A SPIRE2
Sensitivity / hurt feelings	4.26	1	1	2.2	0.00	1.0e+00	LRRC37A
Neuroticism (Nagel 2018)	4.23	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A
Waist Hip Ratio (WHR)	4.04	4	3	6.7	0.55	4.5e-01	AKR1C2 LRRC37A NR5A2 UQCC1
Basal cell carcinoma (self-reported)	3.93	2	2	4.4	0.00	1.0e+00	DPEP1 SPIRE2
Neuroticism score	3.83	1	1	2.2	0.00	1.0e+00	LRRC37A
Blood Red Count	3.76	3	1	2.2	0.00	1.0e+00	LRRC37A NR5A2 SPIRE2
Hair/balding pattern: Pattern 2	3.72	1	1	2.2	0.00	1.0e+00	LRRC37A
Depressed Affect (Nagel 2018)	3.69	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A
Mood swings	3.55	1	1	2.2	0.00	1.0e+00	LRRC37A
Weight	3.45	4	1	2.2	0.24	7.6e-01	AKR1C2 C11orf63 LIN28B UQCC1
Forced expiratory volume in 1-second (FEV1), predicted percentage	3.42	2	1	2.2	0.00	1.0e+00	LRRC37A UQCC1
Forced expiratory volume in 1-second (FEV1)	3.35	3	2	4.4	0.00	1.0e+00	DPEP1 LRRC37A RP11-65J21.3
Forced vital capacity (FVC)	3.34	3	2	4.4	0.00	1.0e+00	DPEP1 LRRC37A RP11-65J21.3
Forced vital capacity (FVC), Best measure	3.21	3	2	4.4	0.00	1.0e+00	LRRC37A RP11-65J21.3 UQCC1
Ovarian Cancer	3.20	1	1	2.2	0.00	1.0e+00	LRRC37A
Guilty feelings	3.05	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A
Impedance of arm (left)	2.99	4	2	4.4	-0.14	8.6e-01	LIN28B LRRC37A SPIRE2 UQCC1
Frequency of tenseness / restlessness in last 2 weeks	2.97	1	1	2.2	0.00	1.0e+00	LRRC37A
Mean Putamen Volume	2.91	1	0	0.0	0.00	1.0e+00	LRRC37A
Headache pain in last month	2.90	1	1	2.2	0.00	1.0e+00	LRRC37A
Knee pain experienced in last month	2.83	1	1	2.2	0.00	1.0e+00	UQCC1
Medication: Paracetamol	2.82	1	1	2.2	0.00	1.0e+00	LRRC37A
Irritability	2.82	1	1	2.2	0.00	1.0e+00	LRRC37A
Worry (Nagel 2018)	2.76	1	1	2.2	0.00	1.0e+00	LRRC37A
Impedance of whole body	2.74	5	3	6.7	-0.15	8.2e-01	DPEP1 LIN28B LRRC37A SPIRE2 UQCC1
Forced expiratory volume in 1-second (FEV1), Best measure	2.72	2	1	2.2	0.00	1.0e+00	LRRC37A RP11-65J21.3
Mouth/teeth dental problems: Mouth ulcers	2.68	1	1	2.2	0.00	1.0e+00	LRRC37A
Trunk fat mass	2.62	5	2	4.4	0.08	9.0e-01	C11orf63 DPEP1 LIN28B SPIRE2 UQCC1
Nervous feelings	2.61	1	0	0.0	0.00	1.0e+00	LRRC37A
Impedance of leg (left)	2.50	4	1	2.2	-0.04	9.6e-01	DPEP1 LIN28B LRRC37A UQCC1
Medication: Paracetamol	2.49	1	1	2.2	0.00	1.0e+00	LRRC37A
Impedance of arm (right)	2.48	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A
Miserableness	2.41	1	1	2.2	0.00	1.0e+00	LRRC37A
Qualifications: CSEs or equivalent	2.35	1	0	0.0	0.00	1.0e+00	LRRC37A
Hearing difficulty/problems with background noise	2.32	1	0	0.0	0.00	1.0e+00	LIN28B
Impedance of leg (right)	2.30	4	1	2.2	-0.02	9.8e-01	DPEP1 LIN28B LRRC37A UQCC1
Comparative body size at age 10	2.28	2	1	2.2	0.00	1.0e+00	C11orf63 LIN28B
Schizophrenia (2014)	2.24	2	0	0.0	0.00	1.0e+00	LIN28B LRRC37A
Medication for pain relief, constipation, heartburn	2.24	1	1	2.2	0.00	1.0e+00	LRRC37A
Fed-up feelings	2.22	1	1	2.2	0.00	1.0e+00	LRRC37A
Heel T-Score	2.19	5	3	6.7	-0.98	5.6e-04	C11orf63 DPEP1 LIN28B LRRC37A SPIRE2
Hip circumference	2.19	1	1	2.2	0.00	1.0e+00	UQCC1
Number of live births	2.19	1	0	0.0	0.00	1.0e+00	LRRC37A
Trunk fat percentage	2.12	4	0	0.0	-0.52	4.8e-01	C11orf63 DPEP1 LRRC37A SPIRE2
Number of operations (self-reported)	2.12	1	0	0.0	0.00	1.0e+00	LIN28B
Friendships satisfaction	2.05	1	0	0.0	0.00	1.0e+00	RP11-65J21.3
Number of treatments/medications taken	2.03	1	0	0.0	0.00	1.0e+00	LIN28B
Primary Biliary Cirrhosis	2.01	1	0	0.0	0.00	1.0e+00	LRRC37A
Ever unenthusiastic/disinterested for a whole week	2.00	1	0	0.0	0.00	1.0e+00	LRRC37A
Neuroticism (2016)	1.91	1	0	0.0	0.00	1.0e+00	LRRC37A
Time employed in main current job	1.89	1	0	0.0	0.00	1.0e+00	LRRC37A
Average weekly champagne plus white wine intake	1.88	1	0	0.0	0.00	1.0e+00	LRRC37A
Age at First Birth	1.86	1	0	0.0	0.00	1.0e+00	SPIRE2
Alcohol intake frequency.	1.84	1	1	2.2	0.00	1.0e+00	LRRC37A
Qualifications: College or University degree	1.83	2	1	2.2	0.00	1.0e+00	HPGDS LRRC37A
Schizophrenia (2018)	1.79	1	0	0.0	0.00	1.0e+00	LIN28B
Worrier / anxious feelings	1.78	1	0	0.0	0.00	1.0e+00	LRRC37A
Whole body fat mass	1.77	3	0	0.0	0.00	1.0e+00	C11orf63 DPEP1 UQCC1
Handedness (chirality/laterality): Left-handed	1.77	1	0	0.0	0.00	1.0e+00	LRRC37A
Heel bone mineral density (BMD) T-score, automated (right)	1.75	1	0	0.0	0.00	1.0e+00	LIN28B
Neck or shoulder pain in last month	1.74	1	0	0.0	0.00	1.0e+00	SPIRE2
Father's age at death	1.72	1	0	0.0	0.00	1.0e+00	ANXA2
Supplements: Vitamin C	1.65	1	0	0.0	0.00	1.0e+00	LRRC37A
Heel bone mineral density (BMD) T-score, automated (left)	1.58	1	0	0.0	0.00	1.0e+00	LIN28B
Loneliness, isolation	1.58	1	0	0.0	0.00	1.0e+00	LRRC37A
Had menopause	1.51	1	0	0.0	0.00	1.0e+00	DPEP1
Body fat percentage	1.49	2	0	0.0	0.00	1.0e+00	C11orf63 SPIRE2
Myopia	1.49	1	0	0.0	0.00	1.0e+00	LRRC37A
Vitamin and mineral supplements	1.47	1	0	0.0	0.00	1.0e+00	LRRC37A
Blood Eosinophil Count	1.36	1	1	2.2	0.00	1.0e+00	LRRC37A
Breast Cancer	1.33	1	0	0.0	0.00	1.0e+00	LRRC37A
Leg fat percentage (left)	1.33	1	0	0.0	0.00	1.0e+00	UQCC1
Systolic Blood Pressure	1.25	1	1	2.2	0.00	1.0e+00	UQCC1
Leg fat percentage (right)	1.25	1	0	0.0	0.00	1.0e+00	UQCC1
Arm fat mass (left)	1.08	1	0	0.0	0.00	1.0e+00	UQCC1
Qualifications: A levels/AS levels or equivalent	1.07	1	0	0.0	0.00	1.0e+00	UQCC1
Arm fat mass (right)	1.03	1	0	0.0	0.00	1.0e+00	UQCC1
Pulse rate, automated reading	0.90	1	0	0.0	0.00	1.0e+00	RP1-199J3.5
Blood White Count	0.85	2	0	0.0	0.00	1.0e+00	LRRC37A SPIRE2
Lung FEV1/FVC ratio	0.73	1	0	0.0	0.00	1.0e+00	LRRC37A
Blood Platelet Count	0.69	2	2	4.4	0.00	1.0e+00	HPGDS LRRC37A

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Hippocampus	5	0.954	2.0
GTEx	Artery Coronary	9	0.761	1.9
GTEx	Brain Frontal Cortex BA9	5	0.541	1.9
GTEx	Brain Hypothalamus	5	0.847	1.9
GTEx	Cells EBV-transformed lymphocytes	9	0.632	1.9
GTEx	Ovary	6	0.661	1.9
GTEx	Small Intestine Terminal Ileum	4	0.868	1.9
GTEx	Uterus	6	1.058	1.9
GTEx	Brain Cortex	7	0.676	1.8
GTEx	Brain Nucleus accumbens basal ganglia	7	0.809	1.8
GTEx	Brain Putamen basal ganglia	5	0.801	1.8
GTEx	Breast Mammary Tissue (Female)	7	0.426	1.8
GTEx	Adipose Visceral Omentum	6	0.295	1.7
GTEx	Brain Caudate basal ganglia	5	0.543	1.7
GTEx	Brain Cerebellar Hemisphere	7	0.470	1.7
GTEx	Brain Cerebellum	6	0.303	1.7
GTEx	Breast Mammary Tissue (Male)	8	0.671	1.7
GTEx	Colon Sigmoid	7	0.479	1.7
GTEx	Colon Transverse	8	0.388	1.7
GTEx	Esophagus Gastroesophageal Junction	7	0.484	1.7
GTEx	Heart Atrial Appendage	7	0.443	1.7
GTEx	Heart Left Ventricle	6	0.392	1.7
GTEx	Pancreas	9	0.551	1.7
GTEx	Pituitary	5	0.448	1.7
GTEx	Prostate	5	0.599	1.7
GTEx	Stomach	7	0.481	1.7
GTEx	Vagina	5	0.787	1.7
GTEx	Adipose Subcutaneous	7	0.201	1.6
GTEx	Adrenal Gland	5	0.343	1.6
GTEx	Artery Aorta	8	0.269	1.6
GTEx	Breast Mammary Tissue	7	0.355	1.6
GTEx	Esophagus Mucosa	10	0.301	1.6
GTEx	Esophagus Muscularis	9	0.278	1.6
GTEx	Liver	4	0.558	1.6
GTEx	Lung	10	0.348	1.6
GTEx	Nerve Tibial	8	0.185	1.6
GTEx	Skin Not Sun Exposed Suprapubic	8	0.325	1.6
GTEx	Spleen	5	0.354	1.6
GTEx	Testis	11	0.349	1.6
GTEx	Thyroid	12	0.300	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	1.6
GTEx	Artery Tibial	5	0.133	1.5
GTEx	Cells Transformed fibroblasts	10	0.238	1.5
GTEx	Muscle Skeletal	9	0.311	1.5
GTEx	Skin Sun Exposed Lower leg	9	0.247	1.5
GTEx	Whole Blood	5	0.251	1.5
ROSMAP	Brain Pre-frontal Cortex	3	0.068	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.391	1.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	9	0.195	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.289	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.238	1.5
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.5
METSIM	Adipose	1	0.022	1.4
NTR	Blood	3	0.125	1.4
YFS	Blood	1	0.022	1.4
CommonMind	Brain Pre-frontal Cortex	4	0.074	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	5	0.113	1.4
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.4
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.4
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	4	0.098	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	4	0.093	1.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	4	0.136	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	4	0.160	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.251	1.4
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.4
The Cancer Genome Atlas	Thyroid Carcinoma	4	0.078	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.3